AureoGen Biosciences announced today that it has been selected to present at the 37th annual Michigan Growth Capital Symposium (MGCS). The company, a small biotech located in Kalamazoo, MI, will present to investors in attendance, which represent more than 100 top venture capital firms. More than 400 entrepreneurs, researchers, investment professionals and business executives are expected to attend the Symposium, which will be held May 15-16 at the Marriott Resort in Ypsilanti, Mich.
First held in 1981, MGCS is the premier, must-attend event for venture capitalists, technology transfer professionals, founders, CEOs and the best of the Midwest early stage and emerging, high-growth companies that are seeking institutional investment. The two-day conference will feature a keynote address from Wendell Brooks, senior VP of Intel Corporation and president of Intel Capital, as well as engaging industry panel discussions and networking opportunities for attendees.
AureoGen Biosciences is a Michigan based biotechnology company that develops novel antibiotics for the treatment of fungal and bacterial infections. The company’s focus is on natural products and the goal of AureoGen’s most important project is to develop broad-spectrum derivatives of the anti-fungal compound Aureobasidin A (AbA), that have the potential to be commercialized as drugs for the treatment of systemic fungal infections. Systemic fungal infections primarily affect individuals with a compromised immune function – most notably cancer and transplantation patients, infants and the elderly. These infections are associated with considerable morbidity and mortality and cause approximately 1.4 million deaths each year world-wide.
AureoGen’ project will be presented by the company CEO, Ake Elhammer. AureoGen is seeking funding for the continued (preclinical and early clinical) development of the company’s lead drug candidate, AUGC-50.
“AureoGen’s drug candidate is doing extremely well and appears to have excellent potential to become a leading performer in therapeutic area that has a very immediate unmet medical need.”
“For nearly four decades, the Symposium has played an essential role in connecting the best and the brightest Midwest entrepreneurs with the investors they need to access new sources of funding to bring their businesses to the next level,” said David Brophy, Michigan Growth Capital Symposium founder and director of the University of Michigan’s Center for Venture Capital & Private Equity. “Once again, I am impressed by the caliber of companies that will be presenting at this year’s event, and we are glad to have AureoGen Biosciences join the ranks.”
To learn more, see the full list of presenting companies or register for the conference, visit www.michigan-gcs.com and follow conversations about the Symposium by tracking #MichiganGCS on Twitter. For more information about AureoGen, please visit www.aureogen.com.